Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors
- PMID: 11780206
Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors
Abstract
Objective: To evaluate the long-term therapeutic effects of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the treatment of hematological and solid tumors.
Methods: Fifty-one patients were recruited in this auto-PBSCT study, in which several potentially important parameters were studied including the optimal time for stem cell collection, the dose of stem cell reinfusion, the time of hematopoietic reconstitution, the disease free survival (DFS) and overall survival (OS), complications related to transplantation, and maintenance chemotherapy after auto-PBSCT.
Results: After APBSCT, 3-year and 5-year survival rates of NHL were 83.3%; those of AML were 74.7%; those of MM were 37.9% and 19%; those of ALL were 40% and 0% respectively. Hematopoietic reconstitution was greatly promoted by granulocyte colony stimulating factor (G-CSF). The mean time for patients' neutrophil to recover up to > 0.5 x 10(9)/L after APBSCT was 11.14 days in the group of the patients receiving G-CSF in contrast to 17.6 days in the group receiving no G-CSF. The most common complications of transplantation were fever, liver dysfunction and hypokalaemia, which were curable. No death was due to transplantation related complications.
Conclusion: Comparing with conventional chemotherapy, our study suggests that auto-PBSCT is a very important therapeutic option that can significantly improve the prognosis in the patients with hematological and solid tumors, especially in the patients with AML and NHL.
Similar articles
-
[An analysis of autologous peripheral stem cell transplantation for hematological malignancies].Zhonghua Xue Ye Xue Za Zhi. 1999 Nov;20(11):586-8. Zhonghua Xue Ye Xue Za Zhi. 1999. PMID: 11721377 Chinese.
-
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001. Biol Blood Marrow Transplant. 2004. PMID: 15148493 Clinical Trial.
-
Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.Bone Marrow Transplant. 2002 May;29(10):825-32. doi: 10.1038/sj.bmt.1703566. Bone Marrow Transplant. 2002. PMID: 12058232
-
[Hematopoietic stem cell transplantation for treatment of acute leukemia].Gan To Kagaku Ryoho. 1999 Sep;26(10):1387-95. Gan To Kagaku Ryoho. 1999. PMID: 10500524 Review. Japanese.
-
Hematopoietic stem cell transplantation in hematologic malignancy.Panminerva Med. 2004 Mar;46(1):61-74. Panminerva Med. 2004. PMID: 15238882 Review.
Cited by
-
Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era.Chin Med J (Engl). 2016 Dec 5;129(23):2780-2785. doi: 10.4103/0366-6999.194661. Chin Med J (Engl). 2016. PMID: 27900988 Free PMC article.